# Clinical Intelligence Platform
## H-34 DELTA Revision Cup Study - POC Design

**Version:** 9.0 | **Date:** January 11, 2026 | **POC Demonstration-Ready Agentic Intelligence Platform**

---

## Executive Summary: Why This Wins

> **This is not a chatbot on a spreadsheet.** This is an **Agentic AI-driven Clinical Intelligence Platform** that transforms how medical device studies are monitored, analyzed, and reported.

### The Problem We Solve

Clinical teams spend **days or weeks** manually:
- Cross-referencing protocol PDFs with Excel exports
- Searching literature for benchmark comparisons
- Compiling regulatory-ready evidence packages
- Identifying patients who need attention

### What We Deliver

| Traditional Approach | Our Platform |
|---------------------|--------------|
| Query one data source at a time | **Multi-source reasoning** across 8 source types |
| Manually read protocol PDF | **Document-as-Code** executes protocol rules automatically |
| Hours to compile status report | **30-second executive briefings** with full provenance |
| Reactive—find problems after they occur | **Proactive alerts** detect signals before they escalate |
| Data only | **Actionable intelligence** with specific recommendations |

### Five Capabilities No One Else Can Deliver

1. **Regulatory Readiness in 30 Seconds** — Gap analysis across protocol + data + literature + registry
2. **Safety Signals with Context** — Not just "rate is high" but "here's why, here's what to do"
3. **Protocol Deviations Detected Automatically** — Document-as-Code validates every patient, every visit
4. **Risk-Stratified Patient Lists** — ML + literature-grounded scoring with explainable factors
5. **Executive Intelligence Dashboard** — One view aggregating 6+ sources into strategic priorities

---

# PART 1: WHAT WE WILL DEMONSTRATE

---

## TOP 5 POC USE CASES

> **Selection Criteria:** These 5 use cases were selected to demonstrate capabilities that (1) CANNOT be achieved with traditional BI or simple chatbots, (2) require multi-source reasoning across structured + unstructured data, (3) leverage Document-as-Code for executable intelligence, and (4) produce concrete, actionable outputs that change clinical and operational decisions.

```
┌─────────────────────────────────────────────────────────────────────────────────────────────────┐
│                              TOP 5 POC USE CASES AT A GLANCE                                     │
├─────────────────────────────────────────────────────────────────────────────────────────────────┤
│                                                                                                  │
│  UC1  REGULATORY SUBMISSION           Multi-source gap analysis producing                       │
│       READINESS ASSESSMENT            actionable remediation checklist                          │
│       ════════════════════════════════════════════════════════════════════════════════════════  │
│                                                                                                  │
│  UC2  SAFETY SIGNAL DETECTION         Cross-source signal correlation with                      │
│       & CONTEXTUALIZATION             literature-grounded risk interpretation                   │
│       ════════════════════════════════════════════════════════════════════════════════════════  │
│                                                                                                  │
│  UC3  AUTOMATED PROTOCOL              Document-as-Code execution detecting                      │
│       DEVIATION DETECTION             and classifying deviations in real-time                   │
│       ════════════════════════════════════════════════════════════════════════════════════════  │
│                                                                                                  │
│  UC4  PATIENT RISK STRATIFICATION     ML + Literature + Registry producing                      │
│       WITH ACTIONABLE MONITORING      prioritized surveillance lists                            │
│       ════════════════════════════════════════════════════════════════════════════════════════  │
│                                                                                                  │
│  UC5  INTELLIGENT STUDY HEALTH        Aggregated multi-source intelligence                      │
│       EXECUTIVE DASHBOARD             with strategic decision support                           │
│       ════════════════════════════════════════════════════════════════════════════════════════  │
│                                                                                                  │
└─────────────────────────────────────────────────────────────────────────────────────────────────┘
```

---

### UC1: Regulatory Submission Readiness Assessment

> **The Business Problem:** Clinical teams spend weeks manually cross-referencing protocol requirements, study data, literature benchmarks, and regulatory expectations to assess submission readiness. Gaps are discovered late, causing delays.

**What Traditional Tools Do:** Generate data listings; user manually compares to protocol PDF.

**What Our Platform Does:**

```
┌─────────────────────────────────────────────────────────────────────────────────────────────────┐
│  USE CASE 1: REGULATORY SUBMISSION READINESS ASSESSMENT                                          │
├─────────────────────────────────────────────────────────────────────────────────────────────────┤
│                                                                                                  │
│  USER QUERY: "Are we ready to submit? What gaps need to be addressed?"                          │
│                                                                                                  │
│  ┌─────────────────────────────────────────────────────────────────────────────────────────┐   │
│  │ AGENT ORCHESTRATION (executes in <30 seconds)                                           │   │
│  ├─────────────────────────────────────────────────────────────────────────────────────────┤   │
│  │                                                                                          │   │
│  │  1. PROTOCOL AGENT: Load protocol_rules.yaml → Extract submission requirements          │   │
│  │     • Primary endpoint: HHS improvement ≥20 points at 2 years                           │   │
│  │     • Sample size: n≥25 evaluable for interim, n=50 for final                          │   │
│  │     • Safety: Complete AE documentation, SAE narratives                                 │   │
│  │     • Radiographic: All timepoint imaging reviewed                                      │   │
│  │                                                                                          │   │
│  │  2. DATA AGENT: Query H-34 study data → Calculate current status                        │   │
│  │     • Primary endpoint: 5/8 achieved MCID (62%), n=8 evaluable                         │   │
│  │     • Safety: 15 AEs documented, 12 SAEs with narratives                               │   │
│  │     • Radiographic: 3 patients missing 1yr imaging                                      │   │
│  │                                                                                          │   │
│  │  3. LITERATURE AGENT: Load literature_benchmarks.yaml → Retrieve comparators            │   │
│  │     • Meding et al: 72% MCID (our 62% within range)                                    │   │
│  │     • Revision rate benchmark: 6.2% (our 8.1% at upper boundary)                        │   │
│  │                                                                                          │   │
│  │  4. REGISTRY AGENT: Load registry_norms.yaml → External validation                      │   │
│  │     • AOANJRR 2yr survival: 94% (our ~92% within CI)                                   │   │
│  │                                                                                          │   │
│  │  5. COMPLIANCE AGENT: Cross-reference all sources → Gap analysis                        │   │
│  │                                                                                          │   │
│  └─────────────────────────────────────────────────────────────────────────────────────────┘   │
│                                                                                                  │
│  ┌─────────────────────────────────────────────────────────────────────────────────────────┐   │
│  │ OUTPUT: SUBMISSION READINESS REPORT                                                      │   │
│  ├─────────────────────────────────────────────────────────────────────────────────────────┤   │
│  │                                                                                          │   │
│  │  OVERALL READINESS: 72% ████████████████░░░░░░░░ (Target: 90% for submission)           │   │
│  │                                                                                          │   │
│  │  ┌─────────────────────────────────────────────────────────────────────────────────┐   │   │
│  │  │ CATEGORY               STATUS    FINDING                      ACTION REQUIRED   │   │   │
│  │  ├─────────────────────────────────────────────────────────────────────────────────┤   │   │
│  │  │ Primary Endpoint       ✅ PASS   62% MCID (≥50% required)     None              │   │   │
│  │  │ Sample Size            🔴 GAP    8/25 evaluable (32%)         Chase 17 patients │   │   │
│  │  │ Literature Benchmark   ✅ PASS   Within published ranges      None              │   │   │
│  │  │ Registry Comparison    ⚠️ WATCH  Revision rate at 95th %ile   Add narrative     │   │   │
│  │  │ Safety Documentation   ✅ PASS   All SAEs have narratives     None              │   │   │
│  │  │ Radiographic Data      🔴 GAP    3 patients missing 1yr       Chase list below  │   │   │
│  │  │ Protocol Deviations    ⚠️ WATCH  4 timing deviations          Document in CSR   │   │   │
│  │  └─────────────────────────────────────────────────────────────────────────────────┘   │   │
│  │                                                                                          │   │
│  │  BLOCKERS (Must resolve before submission):                                              │   │
│  │  1. Sample size: 17 additional patients need 2-year follow-up                           │   │
│  │  2. Radiographic gaps: Patients 12, 19, 27 missing 1-year imaging                       │   │
│  │                                                                                          │   │
│  │  WARNINGS (Should address, not blocking):                                                │   │
│  │  1. Revision rate narrative: Explain 8.1% vs registry 6.2% (early failure cluster)      │   │
│  │  2. Protocol deviations: Document 4 timing deviations in CSR                            │   │
│  │                                                                                          │   │
│  │  PROJECTED READINESS TIMELINE:                                                           │   │
│  │  • Current: 72% ready                                                                    │   │
│  │  • +30 days (chase radiographic): 78% ready                                             │   │
│  │  • +90 days (additional 2yr FU): 85% ready                                              │   │
│  │  • +180 days (target n=25): 92% ready ✅ SUBMISSION VIABLE                              │   │
│  │                                                                                          │   │
│  │  [Download Checklist PDF] [Generate Chase List] [Draft CSR Section] [Email to Team]     │   │
│  │                                                                                          │   │
│  └─────────────────────────────────────────────────────────────────────────────────────────┘   │
│                                                                                                  │
│  PROVENANCE: Protocol (CIP v2.0 Sections 8, 10), Study Data (Sheets 1, 17, 18, 20),            │
│  Literature (Meding 2025, Vasios et al), Registry (AOANJRR 2024)                               │
│                                                                                                  │
└─────────────────────────────────────────────────────────────────────────────────────────────────┘
```

| Aspect | Why This Wins |
|--------|---------------|
| **Multi-Source** | Combines Protocol + Study Data + Literature + Registry in single analysis |
| **Document-as-Code** | Protocol requirements are executable rules, not text to read |
| **Actionable** | Produces specific blockers, chase lists, and timeline projections |
| **Differentiating** | No traditional BI tool can do this; would take analyst days manually |

---

### UC2: Safety Signal Detection & Contextualization

> **The Business Problem:** Safety signals in small studies are hard to interpret without external context. Is a 13% fracture rate concerning? Teams manually search literature and registries for benchmarks.

**What Traditional Tools Do:** Count AEs; user manually researches if rates are normal.

**What Our Platform Does:**

```
┌─────────────────────────────────────────────────────────────────────────────────────────────────┐
│  USE CASE 2: SAFETY SIGNAL DETECTION & CONTEXTUALIZATION                                         │
├─────────────────────────────────────────────────────────────────────────────────────────────────┤
│                                                                                                  │
│  PROACTIVE ALERT (System-Generated, No User Query Required):                                    │
│                                                                                                  │
│  ┌─────────────────────────────────────────────────────────────────────────────────────────┐   │
│  │ 🚨 SAFETY SIGNAL DETECTED: Periprosthetic Fracture Rate Exceeds Benchmarks               │   │
│  ├─────────────────────────────────────────────────────────────────────────────────────────┤   │
│  │                                                                                          │   │
│  │  SIGNAL IDENTIFICATION:                                                                  │   │
│  │  ┌───────────────────────────────────────────────────────────────────────────────────┐  │   │
│  │  │ Metric              H-34 Study    Literature      Registry       Status           │  │   │
│  │  ├───────────────────────────────────────────────────────────────────────────────────┤  │   │
│  │  │ Fracture Rate       13% (5/37)    4-8%            <10%           🔴 ELEVATED      │  │   │
│  │  │ Dislocation Rate    5% (2/37)     3-6%            5%             ✅ NORMAL        │  │   │
│  │  │ Infection Rate      3% (1/37)     2-4%            3%             ✅ NORMAL        │  │   │
│  │  │ Overall AE Rate     35% (13/37)   28-40%          35%            ✅ NORMAL        │  │   │
│  │  └───────────────────────────────────────────────────────────────────────────────────┘  │   │
│  │                                                                                          │   │
│  │  CROSS-SOURCE CONTEXTUALIZATION:                                                         │   │
│  │                                                                                          │   │
│  │  📊 Study Data Analysis:                                                                 │   │
│  │     • 5 periprosthetic fractures in 37 patients (13%)                                   │   │
│  │     • Timing: 4/5 occurred within 90 days (intraop or early postop)                     │   │
│  │     • Pattern: 100% (5/5) occurred in patients with osteoporosis diagnosis              │   │
│  │                                                                                          │   │
│  │  📚 Literature Correlation (Dixon et al 2025, Harris et al 2025):                        │   │
│  │     • Osteoporosis identified as primary risk factor for periprosthetic fracture        │   │
│  │     • Expected rate in osteoporotic patients: 15-20% (vs 4% in non-osteoporotic)       │   │
│  │     • H-34 osteoporosis prevalence: 32% (12/37)—higher than typical study population   │   │
│  │                                                                                          │   │
│  │  📈 Registry Context (AOANJRR 2024):                                                     │   │
│  │     • Overall fracture rate threshold for concern: >10%                                 │   │
│  │     • Risk-adjusted expectation for high-osteoporosis cohort: 10-15%                   │   │
│  │     • H-34 rate (13%) is WITHIN risk-adjusted expectation                              │   │
│  │                                                                                          │   │
│  │  📄 Protocol Check (CIP v2.0 Section 5.2):                                               │   │
│  │     • Osteoporosis is NOT an exclusion criterion                                        │   │
│  │     • No enhanced monitoring protocol specified for bone quality                         │   │
│  │                                                                                          │   │
│  │  ┌───────────────────────────────────────────────────────────────────────────────────┐  │   │
│  │  │ SIGNAL INTERPRETATION                                                              │  │   │
│  │  ├───────────────────────────────────────────────────────────────────────────────────┤  │   │
│  │  │                                                                                    │  │   │
│  │  │ CONFIDENCE: HIGH (3 corroborating sources)                                        │  │   │
│  │  │                                                                                    │  │   │
│  │  │ CONCLUSION: Elevated fracture rate is EXPLAINED by patient population             │  │   │
│  │  │ characteristics (high osteoporosis prevalence), NOT implant failure.              │  │   │
│  │  │ Rate is within literature-predicted range for this risk profile.                  │  │   │
│  │  │                                                                                    │  │   │
│  │  │ REGULATORY IMPLICATION: Signal requires documentation but does not indicate       │  │   │
│  │  │ device defect. Recommend enhanced labeling for osteoporotic patients.             │  │   │
│  │  │                                                                                    │  │   │
│  │  └───────────────────────────────────────────────────────────────────────────────────┘  │   │
│  │                                                                                          │   │
│  │  RECOMMENDED ACTIONS:                                                                    │   │
│  │  1. [Generate Safety Narrative] for regulatory submission                               │   │
│  │  2. [Draft Protocol Amendment] for enhanced bone density screening                      │   │
│  │  3. [Create IFU Update] with osteoporosis precaution language                          │   │
│  │  4. [Flag Similar Patients] (7 remaining with osteoporosis) for enhanced monitoring    │   │
│  │                                                                                          │   │
│  └─────────────────────────────────────────────────────────────────────────────────────────┘   │
│                                                                                                  │
│  PROVENANCE: Study AEs (Sheet 17), Patient diagnoses (Sheet 2), Literature (Dixon 2025,        │
│  Harris 2025), Registry (AOANJRR 2024 Section 4.3), Protocol (CIP v2.0 Section 5.2)           │
│                                                                                                  │
└─────────────────────────────────────────────────────────────────────────────────────────────────┘
```

| Aspect | Why This Wins |
|--------|---------------|
| **Proactive** | System detects and alerts without user query |
| **Multi-Source** | Correlates AE data + patient characteristics + literature + registry + protocol |
| **Contextualized** | Doesn't just flag "high rate"—explains WHY and if it's expected |
| **Actionable** | Specific regulatory and clinical recommendations with one-click generation |

---

### UC3: Automated Protocol Deviation Detection & Classification

> **The Business Problem:** Protocol deviations are identified manually by comparing visit dates to protocol windows—tedious, error-prone, and often discovered late during monitoring visits.

**What Traditional Tools Do:** List visit dates; user manually checks against protocol PDF.

**What Our Platform Does:**

```
┌─────────────────────────────────────────────────────────────────────────────────────────────────┐
│  USE CASE 3: AUTOMATED PROTOCOL DEVIATION DETECTION & CLASSIFICATION                             │
├─────────────────────────────────────────────────────────────────────────────────────────────────┤
│                                                                                                  │
│  DOCUMENT-AS-CODE EXECUTION (Runs automatically on data refresh):                               │
│                                                                                                  │
│  ┌─────────────────────────────────────────────────────────────────────────────────────────┐   │
│  │ PROTOCOL RULES LOADED: protocol_rules.yaml                                               │   │
│  ├─────────────────────────────────────────────────────────────────────────────────────────┤   │
│  │                                                                                          │   │
│  │  Visit Windows (from CIP v2.0 Section 6.2):                                             │   │
│  │  ┌─────────────────────────────────────────────────────────────────────────────────┐   │   │
│  │  │ Visit        Target Day    Window         Required Assessments                   │   │   │
│  │  ├─────────────────────────────────────────────────────────────────────────────────┤   │   │
│  │  │ 2-Month      Day 60        [-14, +28]     HHS, OHS, Radiology, AE Review        │   │   │
│  │  │ 6-Month      Day 180       [-30, +30]     HHS, OHS, Radiology, AE Review        │   │   │
│  │  │ 1-Year       Day 365       [-30, +60]     HHS, OHS, Radiology, AE Review        │   │   │
│  │  │ 2-Year       Day 730       [-60, +60]     HHS, OHS, Radiology, AE Review        │   │   │
│  │  └─────────────────────────────────────────────────────────────────────────────────┘   │   │
│  │                                                                                          │   │
│  │  Deviation Classification (from CIP v2.0 Section 7.2):                                  │   │
│  │  • MINOR: Within 1.5x window extension                                                  │   │
│  │  • MAJOR: Beyond 1.5x window OR missing critical assessment                            │   │
│  │  • CRITICAL: Affects primary endpoint evaluability                                      │   │
│  │                                                                                          │   │
│  └─────────────────────────────────────────────────────────────────────────────────────────┘   │
│                                                                                                  │
│  ┌─────────────────────────────────────────────────────────────────────────────────────────┐   │
│  │ EXECUTION: FOR EACH patient, FOR EACH visit → Validate against rules                    │   │
│  └─────────────────────────────────────────────────────────────────────────────────────────┘   │
│                                                                                                  │
│  ┌─────────────────────────────────────────────────────────────────────────────────────────┐   │
│  │ OUTPUT: PROTOCOL DEVIATION REPORT                                                        │   │
│  ├─────────────────────────────────────────────────────────────────────────────────────────┤   │
│  │                                                                                          │   │
│  │  SUMMARY: 37 patients × 4 visits = 148 visit-assessments evaluated                      │   │
│  │           6 deviations detected (4.1% deviation rate)                                   │   │
│  │                                                                                          │   │
│  │  ┌─────────────────────────────────────────────────────────────────────────────────┐   │   │
│  │  │ DEVIATION DETAIL                                                                 │   │   │
│  │  ├───────┬────────┬──────────┬──────────┬─────────┬────────────┬───────────────────┤   │   │
│  │  │ Pat   │ Visit  │ Expected │ Actual   │ Delta   │ Class      │ Impact            │   │   │
│  │  ├───────┼────────┼──────────┼──────────┼─────────┼────────────┼───────────────────┤   │   │
│  │  │ 15    │ 6mo    │ Mar 15   │ Apr 22   │ +38d    │ MINOR      │ Within tolerance  │   │   │
│  │  │ 22    │ 1yr    │ Aug 10   │ Oct 25   │ +76d    │ MAJOR      │ Outside window    │   │   │
│  │  │ 8     │ 2mo    │ Nov 20   │ Dec 28   │ +38d    │ MINOR      │ Within tolerance  │   │   │
│  │  │ 19    │ 1yr    │ Jun 05   │ MISSING  │ N/A     │ MAJOR      │ Assessment gap    │   │   │
│  │  │ 12    │ 1yr    │ Jul 18   │ Jul 18   │ 0d      │ —          │ Radiology MISSING │   │   │
│  │  │ 27    │ 6mo    │ Feb 28   │ Mar 15   │ +15d    │ MINOR      │ Within tolerance  │   │   │
│  │  └───────┴────────┴──────────┴──────────┴─────────┴────────────┴───────────────────┘   │   │
│  │                                                                                          │   │
│  │  DEVIATION BREAKDOWN:                                                                    │   │
│  │  • MINOR: 3 (timing within extended window—document only)                               │   │
│  │  • MAJOR: 2 (outside window or missing visit—requires explanation)                      │   │
│  │  • CRITICAL: 1 (Patient 12 missing radiology affects endpoint)                          │   │
│  │                                                                                          │   │
│  │  AUTOMATED OUTPUTS GENERATED:                                                            │   │
│  │  ✅ PD Log entries pre-populated (requires PI signature)                                │   │
│  │  ✅ Site query forms generated for MAJOR/CRITICAL deviations                            │   │
│  │  ✅ CSR deviation table updated                                                          │   │
│  │  ✅ Monitoring visit agenda updated with deviation review items                          │   │
│  │                                                                                          │   │
│  │  [Download PD Log] [Send Site Queries] [Update CSR] [View Trends by Visit Type]         │   │
│  │                                                                                          │   │
│  └─────────────────────────────────────────────────────────────────────────────────────────┘   │
│                                                                                                  │
│  PROVENANCE: Protocol rules (CIP v2.0 Sections 6.2, 7.2), Surgery dates (Sheet 4),             │
│  Visit dates (Sheets 7-16), Assessment completion (all follow-up sheets)                       │
│                                                                                                  │
└─────────────────────────────────────────────────────────────────────────────────────────────────┘
```

| Aspect | Why This Wins |
|--------|---------------|
| **Document-as-Code** | Protocol windows are executable rules, not text to interpret |
| **Automated** | Runs on every data refresh—deviations caught in real-time, not at monitoring visits |
| **Classified** | System applies protocol-defined severity categories automatically |
| **Integrated** | Outputs feed directly into PD logs, site queries, CSR—no manual transcription |

---

### UC4: Patient Risk Stratification with Actionable Monitoring Lists

> **The Business Problem:** Which patients need enhanced monitoring? Without predictive tools, all patients get the same attention, wasting resources on low-risk patients while missing early warning signs in high-risk patients.

**What Traditional Tools Do:** List all patients; user subjectively prioritizes.

**What Our Platform Does:**

```
┌─────────────────────────────────────────────────────────────────────────────────────────────────┐
│  USE CASE 4: PATIENT RISK STRATIFICATION WITH ACTIONABLE MONITORING LISTS                        │
├─────────────────────────────────────────────────────────────────────────────────────────────────┤
│                                                                                                  │
│  USER QUERY: "Which patients should I be most concerned about?"                                 │
│                                                                                                  │
│  ┌─────────────────────────────────────────────────────────────────────────────────────────┐   │
│  │ MULTI-MODEL RISK SCORING                                                                 │   │
│  ├─────────────────────────────────────────────────────────────────────────────────────────┤   │
│  │                                                                                          │   │
│  │  Model 1: ML Revision Risk (XGBoost, trained on 737 patients)                           │   │
│  │  Model 2: Literature Risk Factors (Dixon et al, Harris et al hazard ratios)             │   │
│  │  Model 3: Registry Benchmarks (AOANJRR risk-adjusted expectations)                      │   │
│  │  Model 4: Protocol Compliance (deviation accumulation score)                            │   │
│  │                                                                                          │   │
│  │  Combined Score = Weighted ensemble with uncertainty quantification                      │   │
│  │                                                                                          │   │
│  └─────────────────────────────────────────────────────────────────────────────────────────┘   │
│                                                                                                  │
│  ┌─────────────────────────────────────────────────────────────────────────────────────────┐   │
│  │ OUTPUT: PRIORITIZED PATIENT MONITORING LIST                                              │   │
│  ├─────────────────────────────────────────────────────────────────────────────────────────┤   │
│  │                                                                                          │   │
│  │  🔴 HIGH PRIORITY (Enhanced Surveillance Required) — 4 patients                         │   │
│  │  ┌─────────────────────────────────────────────────────────────────────────────────┐   │   │
│  │  │ Patient │ Risk   │ Key Factors                         │ Recommended Action     │   │   │
│  │  ├─────────┼────────┼─────────────────────────────────────┼────────────────────────┤   │   │
│  │  │ 19      │ 28%    │ BMI 36 + Osteoporosis + Zone 2      │ Urgent radiology review│   │   │
│  │  │         │        │ lucency at 6mo + slow HHS recovery  │ + clinical assessment  │   │   │
│  │  ├─────────┼────────┼─────────────────────────────────────┼────────────────────────┤   │   │
│  │  │ 8       │ 24%    │ HHS 'Very Poor' at 1yr (38) +       │ Non-implant cause      │   │   │
│  │  │         │        │ Baseline HHS 25 + Re-revision case  │ workup recommended     │   │   │
│  │  ├─────────┼────────┼─────────────────────────────────────┼────────────────────────┤   │   │
│  │  │ 22      │ 22%    │ HHS trajectory 2.1 SD below mean +  │ Expedite 1yr visit     │   │   │
│  │  │         │        │ BMI 34 + Missed 1yr visit (overdue) │ + retention outreach   │   │   │
│  │  ├─────────┼────────┼─────────────────────────────────────┼────────────────────────┤   │   │
│  │  │ 15      │ 19%    │ Score regression (58→52) + matches  │ Enhanced 2yr monitoring│   │   │
│  │  │         │        │ 'poor responder' trajectory cluster │ protocol               │   │   │
│  │  └─────────────────────────────────────────────────────────────────────────────────┘   │   │
│  │                                                                                          │   │
│  │  🟡 MODERATE PRIORITY (Standard Monitoring + Watch) — 12 patients                       │   │
│  │  • Patients with 1-2 risk factors but stable trajectories                              │   │
│  │  • [View List] [Download for Site]                                                      │   │
│  │                                                                                          │   │
│  │  🟢 LOW PRIORITY (Standard Protocol) — 21 patients                                      │   │
│  │  • On-track recovery, no elevated risk factors                                          │   │
│  │  • [View List]                                                                           │   │
│  │                                                                                          │   │
│  │  ┌───────────────────────────────────────────────────────────────────────────────────┐  │   │
│  │  │ RISK FACTOR CONTRIBUTION ANALYSIS (Patient 19 Example)                            │  │   │
│  │  ├───────────────────────────────────────────────────────────────────────────────────┤  │   │
│  │  │                                                                                    │  │   │
│  │  │  Base risk (cohort average):                    8%  ████                          │  │   │
│  │  │  + BMI 36 (HR 1.6 per AOANJRR):               +5%  ██                             │  │   │
│  │  │  + Osteoporosis (HR 2.4 per Dixon):           +8%  ████                           │  │   │
│  │  │  + Progressive lucency (literature signal):   +4%  ██                             │  │   │
│  │  │  + Slow HHS recovery (ML trajectory):         +3%  █                              │  │   │
│  │  │  ─────────────────────────────────────────────────────                            │  │   │
│  │  │  Total predicted risk:                        28%  ██████████████                 │  │   │
│  │  │                                                                                    │  │   │
│  │  │  Confidence: 78% (validated on synthetic + real data)                             │  │   │
│  │  │                                                                                    │  │   │
│  │  └───────────────────────────────────────────────────────────────────────────────────┘  │   │
│  │                                                                                          │   │
│  │  [Generate Enhanced Monitoring Protocol] [Email Site with Priority List]                │   │
│  │  [Schedule Follow-up Calls] [Export to Clinical Dashboard]                              │   │
│  │                                                                                          │   │
│  └─────────────────────────────────────────────────────────────────────────────────────────┘   │
│                                                                                                  │
│  PROVENANCE: ML model (trained on synthetic data), Literature HRs (Dixon, Harris, Meding),     │
│  Registry norms (AOANJRR), Study data (Sheets 1, 2, 17, 18, radiology sheets)                 │
│                                                                                                  │
└─────────────────────────────────────────────────────────────────────────────────────────────────┘
```

| Aspect | Why This Wins |
|--------|---------------|
| **Explainable** | Shows exactly which factors contribute to each patient's risk score |
| **Literature-Grounded** | Risk factors come from published hazard ratios, not black-box ML |
| **Actionable** | Specific recommendations per patient, not just a number |
| **Prioritized** | Clinical team knows exactly where to focus limited resources |

---

### UC5: Intelligent Study Health Executive Dashboard

> **The Business Problem:** Executives need a single view of study status, but information is scattered across data exports, protocol documents, safety databases, and regulatory trackers. Preparing a status update takes days.

**What Traditional Tools Do:** Multiple reports that don't talk to each other; manual synthesis required.

**What Our Platform Does:**

```
┌─────────────────────────────────────────────────────────────────────────────────────────────────┐
│  USE CASE 5: INTELLIGENT STUDY HEALTH EXECUTIVE DASHBOARD                                        │
├─────────────────────────────────────────────────────────────────────────────────────────────────┤
│                                                                                                  │
│  REAL-TIME AGGREGATED INTELLIGENCE (Updates automatically on data refresh)                      │
│                                                                                                  │
│  ┌─────────────────────────────────────────────────────────────────────────────────────────┐   │
│  │                                                                                          │   │
│  │   H-34 DELTA REVISION CUP STUDY — EXECUTIVE INTELLIGENCE BRIEFING                       │   │
│  │   Generated: January 11, 2026 14:32 UTC | Data as of: January 10, 2026                  │   │
│  │                                                                                          │   │
│  │  ╔═══════════════════════════════════════════════════════════════════════════════════╗ │   │
│  │  ║                                                                                    ║ │   │
│  │  ║   OVERALL STUDY HEALTH:  72/100  ▓▓▓▓▓▓▓▓▓▓▓▓▓▓░░░░░░  GOOD (Target: 80)         ║ │   │
│  │  ║                                                                                    ║ │   │
│  │  ╠════════════════════════════════════════════════════════════════════════════════════╣ │   │
│  │  ║                                                                                    ║ │   │
│  │  ║   📊 ENROLLMENT        37/50  ████████████████░░░░  74%  On Track               ║ │   │
│  │  ║   🎯 EFFICACY          62%    █████████████░░░░░░░  MCID Achieved (n=8)          ║ │   │
│  │  ║   ⚠️ SAFETY            35%    AE rate within range; fracture signal monitored    ║ │   │
│  │  ║   📋 COMPLIANCE        96%    2 minor deviations; 100% SAE reporting             ║ │   │
│  │  ║   📁 DATA QUALITY      87%    23 queries open; 3 critical                        ║ │   │
│  │  ║                                                                                    ║ │   │
│  │  ╚════════════════════════════════════════════════════════════════════════════════════╝ │   │
│  │                                                                                          │   │
│  │  ┌─────────────────────────────────────────────────────────────────────────────────┐   │   │
│  │  │ 🚨 ATTENTION REQUIRED (Aggregated from all sources)                              │   │   │
│  │  ├─────────────────────────────────────────────────────────────────────────────────┤   │   │
│  │  │                                                                                  │   │   │
│  │  │ 1. 🔴 SAMPLE SIZE GAP: Only 8/25 patients at 2-year endpoint (32%)              │   │   │
│  │  │    Source: Study Data + Protocol requirement                                     │   │   │
│  │  │    Impact: Interim analysis delayed until Q3 2026                               │   │   │
│  │  │    Action: [View Retention Plan] [Project Timeline]                             │   │   │
│  │  │                                                                                  │   │   │
│  │  │ 2. 🟡 FRACTURE SIGNAL: 13% rate (literature: 4-8%, but explained by population) │   │   │
│  │  │    Source: AE Data + Literature + Registry + Protocol                           │   │   │
│  │  │    Impact: Requires narrative in CSR; consider protocol amendment               │   │   │
│  │  │    Action: [View Signal Analysis] [Draft Amendment]                             │   │   │
│  │  │                                                                                  │   │   │
│  │  │ 3. 🟡 AT-RISK PATIENTS: 7 patients overdue >60 days                             │   │   │
│  │  │    Source: Visit Data + Protocol windows                                         │   │   │
│  │  │    Impact: Potential loss to follow-up; power reduction if lost                 │   │   │
│  │  │    Action: [View Patient List] [Generate Outreach Plan]                         │   │   │
│  │  │                                                                                  │   │   │
│  │  └─────────────────────────────────────────────────────────────────────────────────┘   │   │
│  │                                                                                          │   │
│  │  ┌─────────────────────────────────────────────────────────────────────────────────┐   │   │
│  │  │ 📈 BENCHMARKING vs EXTERNAL SOURCES                                              │   │   │
│  │  ├─────────────────────────────────────────────────────────────────────────────────┤   │   │
│  │  │                                                                                  │   │   │
│  │  │ Metric            H-34      Literature     Registry      Status                 │   │   │
│  │  │ ─────────────────────────────────────────────────────────────────────────────── │   │   │
│  │  │ HHS Improvement   +34.9     +28 to +45     +32 median    ✅ Mid-range           │   │   │
│  │  │ MCID Rate         62%       60-80%         68% median    ✅ Within range        │   │   │
│  │  │ Revision Rate     8.1%      5-8%           6.2% median   ⚠️ Upper boundary      │   │   │
│  │  │ AE Rate           35%       28-40%         35%           ✅ Expected            │   │   │
│  │  │ 2yr Survival      92%       90-96%         94%           ✅ Within CI           │   │   │
│  │  │                                                                                  │   │   │
│  │  │ Sources: Meding 2025, Vasios et al, Harris 2025, Dixon 2025, AOANJRR 2024       │   │   │
│  │  │                                                                                  │   │   │
│  │  └─────────────────────────────────────────────────────────────────────────────────┘   │   │
│  │                                                                                          │   │
│  │  ┌─────────────────────────────────────────────────────────────────────────────────┐   │   │
│  │  │ 📅 REGULATORY TIMELINE                                                           │   │   │
│  │  ├─────────────────────────────────────────────────────────────────────────────────┤   │   │
│  │  │                                                                                  │   │   │
│  │  │ Today ──────●───────────────────────────────────────────────────────────────▶   │   │   │
│  │  │             │                                                                    │   │   │
│  │  │      Q1 2026│  Q2 2026      Q3 2026      Q4 2026      Q1 2027      Q2 2027     │   │   │
│  │  │             │                                                                    │   │   │
│  │  │             ├─ n=15 eval ───├─ n=25 interim ───├─ n=35 ───├─ CSR draft ───├─ Submit │   │
│  │  │                             │ (Current target)                                   │   │   │
│  │  │                                                                                  │   │   │
│  │  │ Status: ON TRACK with 2-month buffer                                            │   │   │
│  │  │ Risk: Follow-up attrition could erode buffer                                    │   │   │
│  │  │                                                                                  │   │   │
│  │  └─────────────────────────────────────────────────────────────────────────────────┘   │   │
│  │                                                                                          │   │
│  │  [Download Executive Summary PDF] [Schedule Review Meeting] [Drill Down to Details]     │   │
│  │  [Compare to Last Month] [Export for Board Presentation]                                │   │
│  │                                                                                          │   │
│  └─────────────────────────────────────────────────────────────────────────────────────────┘   │
│                                                                                                  │
│  PROVENANCE: This dashboard aggregates 6 data sources automatically:                            │
│  Study Data (21 sheets), Protocol (CIP v2.0), Literature (15 PDFs), Registry (AOANJRR),        │
│  EC Documents (approval status), Prior Reports (Intermediate Report Dec 2023)                  │
│                                                                                                  │
└─────────────────────────────────────────────────────────────────────────────────────────────────┘
```

| Aspect | Why This Wins |
|--------|---------------|
| **Aggregated** | Single view synthesizes 6+ data sources into actionable summary |
| **Contextualized** | Every metric shown with literature/registry comparison |
| **Proactive** | Highlights issues requiring attention, not just data |
| **Executive-Ready** | One-click export for board presentations, regulatory meetings |

---

### Summary: Why These 5 Use Cases Win

| UC | Capability Demonstrated | Traditional Approach | Time Saved | Strategic Value |
|----|------------------------|---------------------|------------|-----------------|
| **UC1** | Multi-source regulatory readiness | 3-5 days manual assembly | 95% | Catch gaps before they cause delays |
| **UC2** | Cross-source safety contextualization | Weeks of literature review | 90% | Explain signals, avoid false alarms |
| **UC3** | Document-as-Code deviation detection | Hours per monitoring visit | 99% | Real-time compliance, not retrospective |
| **UC4** | ML + Literature risk stratification | Subjective clinical judgment | 80% | Focus resources on high-risk patients |
| **UC5** | Aggregated executive intelligence | Days of report preparation | 95% | Strategic decisions with full context |

**Combined Value Proposition:**

> These 5 use cases transform clinical study operations from **reactive data retrieval** to **proactive, contextualized, actionable intelligence**. Each use case demonstrates capabilities that CANNOT be achieved with traditional BI tools, simple chatbots, or RAG-only approaches. The platform doesn't just answer questions—it **anticipates needs, correlates sources, and drives decisions**.

---

# PART 2: HOW WE DO IT (Key Differentiators)

---

## Multi-Source Data Architecture

> **The Core Challenge:** Traditional BI systems query ONE data source at a time. Our platform performs **cross-source reasoning**—correlating structured study data with unstructured protocols, literature, and registry benchmarks to surface insights that NO SINGLE SOURCE can provide.

### Available Data Sources for H-34 POC

```
┌─────────────────────────────────────────────────────────────────────────────────────────────────┐
│                         MULTI-SOURCE CLINICAL INTELLIGENCE ARCHITECTURE                          │
├─────────────────────────────────────────────────────────────────────────────────────────────────┤
│                                                                                                  │
│  ┌──────────────────────────┐   ┌──────────────────────────┐   ┌──────────────────────────┐    │
│  │   📊 STRUCTURED DATA     │   │   📄 PROTOCOL DOCUMENTS   │   │   📚 LITERATURE PDFs     │    │
│  │   (H-34 Excel Export)    │   │   (RAG-indexed)          │   │   (RAG-indexed)          │    │
│  ├──────────────────────────┤   ├──────────────────────────┤   ├──────────────────────────┤    │
│  │ • Patient demographics   │   │ • CIP v2.0 (Nov 2024)    │   │ • Meding et al 2025      │    │
│  │ • HHS/OHS scores (5 pts) │   │ • Schedule of Assessments│   │ • Dixon et al 2025       │    │
│  │ • Radiographic evals     │   │ • Endpoint definitions   │   │ • Vasios et al           │    │
│  │ • Adverse events         │   │ • Visit windows          │   │ • Zucchet et al 2025     │    │
│  │ • Revision/explants      │   │ • I/E criteria           │   │ • Harris et al 2025      │    │
│  │ • Batch/lot numbers      │   │ • AE definitions         │   │ • Willems et al 2025     │    │
│  │ • Surgery details        │   │ • Success criteria       │   │ • +10 more publications  │    │
│  └──────────────────────────┘   └──────────────────────────┘   └──────────────────────────┘    │
│              │                             │                             │                      │
│              └─────────────────────────────┼─────────────────────────────┘                      │
│                                            ▼                                                    │
│                              ┌──────────────────────────┐                                       │
│                              │   🤖 AGENTIC AI LAYER    │                                       │
│                              │   (Cross-Source Reasoning)│                                       │
│                              ├──────────────────────────┤                                       │
│                              │ • Protocol Reasoning Agent│                                       │
│                              │ • Data Quality Agent      │                                       │
│                              │ • Safety Signal Agent     │                                       │
│                              │ • Literature Context Agent│                                       │
│                              │ • Narrative Evidence Agent│                                       │
│                              └──────────────────────────┘                                       │
│                                            │                                                    │
│              ┌─────────────────────────────┼─────────────────────────────┐                      │
│              │                             │                             │                      │
│              ▼                             ▼                             ▼                      │
│  ┌──────────────────────────┐   ┌──────────────────────────┐   ┌──────────────────────────┐    │
│  │   📈 REGISTRY DATA       │   │   📋 STUDY REPORTS       │   │   📁 TMF DOCUMENTS       │    │
│  │   (External Benchmarks)  │   │   (Intermediate Results) │   │   (Compliance Checks)    │    │
│  ├──────────────────────────┤   ├──────────────────────────┤   ├──────────────────────────┤    │
│  │ • AOANJRR: 5-8% rev@2yr  │   │ • H-34 Intermediate RPT  │   │ • EC approvals           │    │
│  │ • NJR: UK benchmark data │   │ • Progress reports       │   │ • Protocol deviations log│    │
│  │ • EPRD: Germany data     │   │ • Safety summaries       │   │ • Training logs          │    │
│  │ • Published benchmarks   │   │ • Enrollment updates     │   │ • Monitoring visit logs  │    │
│  └──────────────────────────┘   └──────────────────────────┘   └──────────────────────────┘    │
│                                                                                                  │
└─────────────────────────────────────────────────────────────────────────────────────────────────┘
```

### Why Multi-Source Matters: Single-Source vs Multi-Source Intelligence

| Question Type | Single-Source Answer | Multi-Source Agentic Answer |
|---------------|---------------------|----------------------------|
| "What's our revision rate?" | "8.1% (3/37 patients)" | "8.1% (3/37). **Context:** AOANJRR reports 5-8% for revision THA at 2yr. Our rate is at upper boundary. **Literature:** Meding et al (2025) reports 6.2% for similar cementless cups. **Protocol insight:** All 4 events occurred <90 days, suggesting early mechanical failures rather than long-term wear—different risk profile than registry patterns." |
| "Are outcomes acceptable?" | "Mean HHS +34.9 points" | "Mean HHS improvement +34.9 pts (n=8). **Protocol compliance:** Exceeds 20-point MCID threshold defined in CIP Section 8.2. **Literature context:** Vasios et al reports 28-42 pt improvement range; our results are mid-range. **Registry benchmark:** AOANJRR shows 85% report 'good/excellent' outcomes; our 62% MCID achievement suggests monitoring needed for non-responders." |
| "Any safety concerns?" | "15 AEs, 12 SAEs" | "15 AEs in 13 patients (35%). **Protocol compliance:** All SAEs reported within 24-hour window per CIP Section 9.1. **Literature comparison:** Harris et al (2025) reports 28-40% AE rate for revision THA; we're within range. **Cross-domain signal:** 3/5 periprosthetic fractures occurred in patients with osteoporosis diagnosis—matches risk pattern in Dixon et al. **Registry context:** AOANJRR flags fracture rates >10% as concerning; our 13% warrants enhanced bone quality assessment protocol." |

---

## Document-as-Code: Protocol Digitization & Beyond

> **The Critical Distinction:** RAG retrieval answers "what does the document say?" Document-as-Code answers "what does this mean for my data, and what should I do?" It transforms static PDFs into **executable knowledge models** that drive automated validation, compliance checking, and intelligent automation.

### RAG Retrieval vs Document-as-Code

| Aspect | RAG Retrieval (Standard) | Document-as-Code (Differentiator) |
|--------|--------------------------|-----------------------------------|
| **What it does** | Finds relevant text passages | Extracts structured rules and executes them |
| **Output** | "Section 6.2 says visits should occur at 2mo, 6mo, 1yr, 2yr" | `{"visit_2mo": {"window_days": [-14, 28], "required_forms": ["HHS", "OHS", "Radiology"]}}` |
| **Automation** | Human reads and interprets | System automatically validates data against rules |
| **Compliance** | "The protocol requires X" (informational) | "Patient 15 is OUT OF WINDOW by 8 days" (actionable) |
| **Scalability** | Each query re-searches document | Rules extracted once, applied to all patients instantly |

### Document Digitization Schemas

#### Protocol-as-Code (CIP_H-34_v.2.0)

```yaml
# PROTOCOL DIGITIZATION SCHEMA
protocol:
  id: "H-34"
  version: "2.0"
  title: "DELTA Revision Cup Clinical Investigation"

# SCHEDULE OF ASSESSMENTS → Executable Visit Model
schedule_of_assessments:
  visits:
    - id: "fu_2mo"
      day_offset: 60
      window: [-14, +28]
      required_assessments: ["hhs", "ohs", "radiology", "ae_review"]
    - id: "fu_6mo"
      day_offset: 180
      window: [-30, +30]
      required_assessments: ["hhs", "ohs", "radiology", "ae_review"]
    - id: "fu_1yr"
      day_offset: 365
      window: [-30, +60]
      required_assessments: ["hhs", "ohs", "radiology", "ae_review"]
    - id: "fu_2yr"
      day_offset: 730
      window: [-60, +60]
      required_assessments: ["hhs", "ohs", "radiology", "ae_review"]
      critical: true  # Primary endpoint collection

# ENDPOINT DEFINITIONS → Executable Calculations
endpoints:
  primary:
    id: "hhs_improvement"
    calculation: "hhs_2yr - hhs_baseline"
    success_threshold: 20  # MCID
    success_criterion: "improvement >= 20 points"

# SAFETY THRESHOLDS → Automated Monitoring Triggers
safety_thresholds:
  revision_rate_concern: 0.10  # 10% triggers review
  sae_rate_concern: 0.40       # 40% triggers review
  fracture_rate_concern: 0.08  # 8% triggers bone quality review
```

#### Literature-as-Code (Benchmark Extraction)

```yaml
# LITERATURE DIGITIZATION SCHEMA
publication:
  id: "meding_2025"
  title: "Long-term outcomes of cementless revision THA"

benchmarks:
  outcomes:
    hhs_improvement:
      mean: 38.2
      sd: 14.3
      ci_95: [35.7, 40.7]
    revision_rate:
      value: 0.062  # 6.2%
      ci_95: [0.041, 0.089]
    mcid_achievement:
      value: 0.72  # 72%
```

#### Registry-as-Code (External Validation)

```yaml
# REGISTRY DIGITIZATION SCHEMA
registry:
  id: "aoanjrr_2024"
  name: "Australian Orthopaedic Association National Joint Replacement Registry"

benchmarks:
  revision_tha:
    cementless_cup:
      survival_2yr: 0.94  # 94%
      revision_rate_median: 0.062
      revision_rate_p95: 0.12

risk_factors:
  osteoporosis:
    revision_hr: 1.8
    fracture_hr: 2.4
  bmi_over_35:
    revision_hr: 1.6
```

### Use Cases ONLY Possible with Document-as-Code

| # | Use Case | Why RAG Can't Do This |
|---|----------|----------------------|
| **DC1** | **Automated Visit Window Validation** | RAG returns text "visits should occur within ±30 days"; cannot calculate dates |
| **DC2** | **Real-time Eligibility Re-verification** | RAG can quote I/E criteria text; cannot evaluate patient data |
| **DC3** | **Endpoint Calculation with Protocol-Defined Rules** | RAG describes endpoint; cannot compute |
| **DC4** | **Automated eCRF Edit Check Generation** | RAG can describe requirements; cannot create executable checks |
| **DC5** | **Protocol-Driven Chase List Generation** | RAG states what's required; cannot identify what's missing |
| **DC6** | **Literature-Grounded Outlier Detection** | RAG quotes literature ranges; cannot apply to your data |
| **DC7** | **Registry-Based Risk Stratification** | RAG returns registry statistics; cannot score patients |
| **DC8** | **Automated Deviation Classification** | RAG describes deviation categories; cannot classify |
| **DC9** | **Dynamic Success Criteria Monitoring** | RAG states success criteria; cannot track progress |
| **DC10** | **Cross-Document Rule Conflict Detection** | RAG retrieves independently; cannot compare rules |

---

# PART 3: SUPPORTING TECHNICAL DETAIL

---

## Data Foundation & Constraints

### H-34 Study Data Inventory

| Sheet | Content | Records | Key Fields |
|-------|---------|---------|------------|
| 1 Patients | Demographics | 37 | Age, Gender, BMI, Status |
| 2 Preoperatives | Diagnosis, history | 36 | Primary diagnosis, prior surgeries |
| 3 Radiographical (Preop) | Baseline imaging | 36 | Bone quality, defects |
| 4 Intraoperatives | Surgery details | 36 | Cup/stem type, size, cement |
| 5 Surgery Data | Procedure info | 35 | Approach, duration, complications |
| 6 Batch Numbers | Lot tracking | 33 | 26 unique batch numbers |
| 7-16 Follow-ups | Visit data + Radiology | Varies | By timepoint |
| 17 Adverse Events | Safety events | 15 | 13 patients, 12 SAEs |
| 18 Score HHS | Primary endpoint | 112 | Across 5 timepoints |
| 19 Score OHS | Secondary endpoint | 112 | Across 5 timepoints |
| 20 Explants | Revisions | 4 | 3 unique patients |
| 21 Reimplants | Revision surgery | 3 | Revision implant details |

### Critical Sample Size Constraints

```
┌─────────────────────────────────────────────────────────────────────────────┐
│ DATA AVAILABILITY BY TIMEPOINT                                              │
├─────────────────────────────────────────────────────────────────────────────┤
│                                                                              │
│  HHS Scores:                                                                │
│                                                                              │
│  Preoperative   ████████████████████████████████████  36 patients           │
│  2 Months       █████████████████████████████         29 patients           │
│  6 Months       ████████████████████████              24 patients           │
│  1 Year         ███████████████                       15 patients           │
│  2 Years        ████████                               8 patients  ⚠️        │
│                                                                              │
│  Patients with 3+ timepoints: 23                                            │
│  Patients with all 5 timepoints: 8                                          │
│                                                                              │
├─────────────────────────────────────────────────────────────────────────────┤
│ EVENT COUNTS (For Statistical Modeling)                                     │
├─────────────────────────────────────────────────────────────────────────────┤
│                                                                              │
│  Revisions/Explants:  4 events (3 patients)  ❌ Insufficient for modeling   │
│  Adverse Events:      15 events (13 patients) ⚠️ Limited for pattern detect │
│  SAEs:                12 events               ⚠️ Descriptive only           │
│                                                                              │
│  Minimum for Cox PH regression: ~10 events per covariate                    │
│  Minimum for ML classification: ~50+ events                                 │
│  Current revision events: 4  → INSUFFICIENT                                 │
│                                                                              │
└─────────────────────────────────────────────────────────────────────────────┘
```

### Capability Feasibility Matrix

**With Real Data Only (37 patients):**

| Capability | Status | Constraint |
|------------|--------|------------|
| Cox PH risk factors | ❌ NOT FEASIBLE | 4 events, need 10+ per covariate |
| ML risk prediction | ❌ NOT FEASIBLE | 4 events cannot train a model |
| Trajectory clustering | ⚠️ MARGINAL | Only 8 patients with 5 timepoints |
| Descriptive statistics | ✅ FEASIBLE | Full dataset available |
| Literature comparison | ✅ FEASIBLE | External data available |

**With Synthetic Data Augmentation (737 total: 37 real + 700 synthetic):**

| Capability | Status | Data Available |
|------------|--------|----------------|
| Cox PH risk factors | ✅ FEASIBLE | 60 revision events |
| ML risk prediction | ✅ FEASIBLE | 60 events for training/validation |
| Trajectory clustering | ✅ FEASIBLE | 102 patients with complete trajectories |
| 2-Year outcome forecasting | ✅ FEASIBLE | 277 patients with 2-year outcomes |

> **Transparency:** Synthetic data is generated from real H-34 distributions + published literature benchmarks. All synthetic records marked with `is_synthetic=True`.

---

## Validated Capability Matrix

### REACTIVE: Agentic Question-Answering

| Tier | Question Type | Example | Data Sources |
|------|---------------|---------|--------------|
| **TIER 0** | Multi-Source Intelligence | "How do we compare to published literature and registry benchmarks?" | Protocol + Study + Literature + Registry |
| **TIER 1** | Cross-Domain Clinical | "Are we on track to meet the primary endpoint?" | Study data + Literature benchmarks |
| **TIER 2** | Protocol-Aware Management | "What protocol deviations might exist?" | Protocol rules + Visit data |
| **TIER 3** | Safety Signal Intelligence | "Analyze AEs and identify clustering patterns" | AE data + Demographics + Radiology |
| **TIER 4** | Data Quality | "Generate data quality report" | All study data sheets |

### PROACTIVE: Intelligent Surveillance

| Tier | Alert Type | Example | Sources Monitored |
|------|------------|---------|-------------------|
| **TIER 0** | Multi-Source Autonomous | Protocol-Literature Divergence Alert | Study + Protocol + Literature + Registry |
| **TIER 1** | Cross-Domain Safety | Outcome-Radiographic Discordance | HHS scores + Radiology |
| **TIER 2** | Study Execution | Endpoint Evaluability at Risk | Visit completion + Protocol windows |
| **TIER 3** | Predictive Early Warning | Elevated Revision Risk Identified | ML model + Clinical data |

### PREDICTIVE: ML/Analytics Capabilities

| Capability | Business Question | Technology | Data Required |
|------------|-------------------|------------|---------------|
| Enrollment Forecasting | "When will we reach target?" | Prophet | Real data (36 surgeries) |
| Survival Analysis | "What is implant survival?" | Kaplan-Meier | Real data (descriptive) |
| Risk Prediction | "Which patients need monitoring?" | XGBoost | Synthetic data (60 events) |
| Trajectory Classification | "What recovery pattern?" | K-Means | Synthetic data (102 complete) |

---

## Technology Stack

| Component | Technology | Purpose |
|-----------|------------|---------|
| **LLM** | Gemini 2.5 Pro | Natural language understanding, response generation |
| **RAG** | ChromaDB + text-embedding-004 | Document retrieval (protocol, literature) |
| **Time Series** | Prophet | Enrollment forecasting |
| **Survival** | lifelines | Kaplan-Meier curves |
| **ML** | XGBoost, scikit-learn | Risk prediction, clustering |
| **Backend** | FastAPI | API layer |
| **Frontend** | Streamlit | Demo interface |

---

## RFP Alignment

### High-Priority Use Cases — Direct Coverage

| Client Requirement | Our Capability | POC Demonstration |
|--------------------|----------------|-------------------|
| Manage, interpret, organize large data volumes | Multi-source data fusion | Cross-domain queries across 21 sheets |
| Identify trends, correlations, outliers | Anomaly detection, trajectory analysis | Discordance detection, AE clustering |
| Generate automated reports | Templated report generation with provenance | Query-to-insight with traceability |
| Provide clinical insights via chatbot | Natural language Q&A with provenance | All REACTIVE questions |
| Stratify/analyze clinical study data | Subgroup analysis, risk stratification | Individual risk scoring |

### Agentic AI Differentiation — What Traditional BI Cannot Do

| Capability | Traditional BI | Our Agentic AI Platform |
|------------|----------------|------------------------|
| **Cross-domain reasoning** | Manual joins, separate queries | Single question spans outcomes + radiology + safety |
| **Literature-grounded context** | Not available | Automatic comparison to published benchmarks |
| **Natural language** | Requires SQL/query building | Ask in plain English, get cited answers |
| **Predictive intelligence** | Static thresholds | ML-based risk scoring with uncertainty |
| **Proactive surveillance** | Scheduled reports only | Autonomous pattern detection with alerts |
| **Protocol awareness** | Manual compliance checks | Document-as-Code executes rules automatically |
| **Actionable recommendations** | Data only | "Do this next" with clinical rationale |

### POC Scope Coverage

| RFP Category | Total Prompts | Covered by POC | Coverage |
|--------------|---------------|----------------|----------|
| Data Management | 12 | 11 | 92% |
| Statistical Analysis | 8 | 8 | 100% |
| Data Interpretation | 4 | 4 | 100% |
| Study Management | 11 | 8 | 73% |
| Information/Strategy | 3 | 2 | 67% |
| Regulatory | 2 | 1 | 50% |
| **TOTAL** | **40** | **34** | **85%** |

---

## Success Criteria

| Criterion | Target | Measurement |
|-----------|--------|-------------|
| Q&A accuracy (deterministic) | 100% | Exact match to source data |
| Q&A accuracy (LLM synthesis) | >90% | Expert review |
| Response time | <10 seconds | Timing |
| Provenance completeness | 100% | Every answer cites source |
| Honest uncertainty | 100% | System never overstates confidence |

---

*Version 9.0 — POC Demonstration-Ready Agentic Intelligence Platform*

**Document Structure (v9.0):**
- **PART 1: What We Will Demonstrate** — TOP 5 POC Use Cases (UC1-UC5) showcasing multi-source reasoning, Document-as-Code, and actionable intelligence
- **PART 2: How We Do It** — Key differentiators (Multi-Source Architecture, Document-as-Code)
- **PART 3: Supporting Technical Detail** — Data constraints, capability matrix, technology stack, RFP alignment

**Version History:**
- v9.0: Restructured for impact — Use cases to top, supporting detail to bottom
- v8.0: Added TOP 5 POC USE CASES (UC1-UC5)
- v7.0: Added Document-as-Code digitization schemas
- v6.0: Added Multi-Source Architecture and TIER 0 capabilities

**Document Digitization Targets:**
- `protocol_rules.yaml` — CIP v2.0 (visit windows, endpoints, eligibility, safety thresholds)
- `literature_benchmarks.yaml` — 15 publications (outcome benchmarks, risk factors)
- `registry_norms.yaml` — AOANJRR/NJR (survival curves, percentiles, HRs)

*Real data: H-34DELTARevisionstudy_export_20250912.xlsx (N=37)*
*Synthetic data: H-34_SYNTHETIC_PRODUCTION.xlsx (N=700)*
*Unstructured sources: 15 Literature PDFs, Protocol v2.0, Registry reports, EC documents*
*Data audit date: January 11, 2026*
